NantKwest (NK) IPO Opens Up 48%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NantKwest Inc. (Nasdaq: NK) to Ring The Nasdaq Stock Market Closing Bell
July 28, 2015 6:00 AM EDTADVISORY, July 28, 2015 (GLOBE NEWSWIRE) --
What:  NantKwest (Nasdaq: NK), is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the bodys first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.
NantKwests unique NK cell based platform, with the capacity to grow active killer cells... More
NantKwest Inc. (Nasdaq: NK) to Ring The Nasdaq Stock Market Closing Bell
July 28, 2015 6:00 AM EDTADVISORY, July 28, 2015 (GLOBE NEWSWIRE) --
What:  NantKwest (Nasdaq: NK), is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the bodys first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.
NantKwests unique NK cell based platform, with the capacity to grow active killer cells... More
NantKwest Announces Pricing of Initial Public Offering
July 28, 2015 1:38 AM EDTCULVER CITY, Calif.--(BUSINESS WIRE)-- NantKwest, Inc. (formerly Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, announced today the pricing of its initial public offering of 8,288,000 shares of its common stock at a price to the public of $25.00 per share. All of the shares are being offered by NantKwest. The shares are expected to begin trading on The Nasdaq Global Select Market on July 28, 2015, under the symbol "NK." In addition, NantKwest has granted the underwriters... More
